Physician profile
Jessica Crystal
NPI 1285947945
$932.70
in general payments reported to CMS, 2019-2025
12 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.64 · 2022: $46.58 · 2023: $328 · 2024: $312 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endomagnetics LTD | $216.89 | 2023-2025 | Magtrace, Magseed, Sentimag |
| Regeneron Healthcare Solutions, INC. | $119.04 | 2024 | Libtayo |
| Janssen Biotech, INC. | $110.78 | 2021-2023 | Darzalex, Tecvayli |
| Pacira Pharmaceuticals Incorporated | $107.88 | 2025 | Exparel |
| Pfizer INC. | $104.24 | 2023 | |
| Novartis Pharmaceuticals Corporation | $72.82 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $65.93 | 2024 | Amtagvi |
| Tempus Ai, INC | $40.42 | 2024 | Xt Cdx |
| Tersera Therapeutics LLC | $30.68 | 2025 | Zoladex |
| Hologic Sales and Service, LLC | $26.10 | 2023 | 3dimensions, Brevera Breast Biopsy System |
| Boston Scientific Corporation | $21.88 | 2024 | Spaceoar Vue System - 10ml |
| Stemline Therapeutics INC. | $16.04 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Crystal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.